The study found that antilipoprotein lipase (anti-LPL) was associated with oxidatively modified LDL, production of antioxidized LDL antibodies, CIMT, and coronary risk in some SLE patients (15, 26). This evidence concerns the gene LPL and systemic lupus erythematosus.